Dogwood Therapeutics (Nasdaq:DWTX) - Aandelenkoers, Nieuws & Analyse

DWTX Overzicht aandelen

DWTX fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Risicoanalyse

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the US market

Has less than 1 year of cash runway

Does not have a meaningful market cap ($6M)

+ 3 meer risico's

Dogwood Therapeutics, Inc. Concurrenten

Portage Biotech

NasdaqCM:PRTG

US$5.9m

Sunshine Biopharma

NasdaqCM:SBFM

US$5.7m

Exicure

NasdaqCM:XCUR

US$5.8m

Enzon Pharmaceuticals

OTCPK:ENZN

US$6.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Dogwood Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$4.37
52 Week Hoogtepunt	US$26.00
52 Week Laag	US$2.50
Bèta	1.58
11 maand verandering	3.31%
3 maanden verandering	-10.04%
1 Jaar Verandering	-77.15%
33 jaar verandering	-96.93%
5 jaar verandering	n/a
Verandering sinds IPO	-98.95%

Recent nieuws en updates

Recent updates

Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Jun 25

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Mar 09

Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Nov 02

Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Jul 19

Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study

Jun 04

Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans

Mar 31

Virios Therapeutics gains 10% on research deal in irritable bowel syndrome

Feb 01

Virios Therapeutics prices IPO at $10

Dec 17

Rendement voor aandeelhouders

	DWTX	US Biotechs	US Markt
7D	-10.3%	-0.7%	-1.6%
1Y	-77.2%	19.8%	30.8%

Rendement versus industrie: DWTX underperformed the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: DWTX underperformed the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is DWTX's price volatile compared to industry and market?
DWTX volatility
DWTX Average Weekly Movement	19.7%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: DWTX's share price has been volatile over the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: DWTX's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2012	4	Greg Duncan	www.dwtx.com

Dogwood Therapeutics, Inc., een biotechnologiebedrijf in een ontwikkelingsstadium, richt zich op de ontwikkeling van nieuwe antivirale therapieën voor de behandeling van ziekten die gepaard gaan met een door virussen veroorzaakte abnormale immuunrespons. De belangrijkste ontwikkelingskandidaat van het bedrijf is IMC-1, een combinatie van famciclovir en celecoxib in vaste dosering voor de behandeling van fibromyalgie. Het ontwikkelt ook IMC-2, een combinatie van valacyclovir en celecoxib voor de behandeling van de vermoeidheid, slaap, aandacht, pijn, autonome functie en angst die gepaard gaan met lange COVID.

Dogwood Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Dogwood Therapeutics zich tot de beurswaarde?
DWTX fundamentele statistieken
Marktkapitalisatie	US$5.82m
Inkomsten(TTM)	-US$4.68m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.2x

Koers/Winstverhouding

Is DWTX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
DWTX resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$4.68m
Inkomsten	-US$4.68m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 07, 2024

Winst per aandeel (EPS)	-3.51
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde DWTX op de lange termijn?

Bekijk historische prestaties en vergelijking

DWTX Overzicht aandelen

Beloningen

Risicoanalyse

Dogwood Therapeutics, Inc. Concurrenten

NasdaqCM:PRTG

US$5.9m

NasdaqCM:SBFM

US$5.7m

NasdaqCM:XCUR

US$5.8m

OTCPK:ENZN

US$6.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Dogwood Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Price target increased by 92% to US$83.33

Virios Therapeutics, Inc. Appoints Angela Walsh as Chief Financial Officer

Virios Therapeutics, Inc. (NasdaqCM:VIRI) acquired Pharmagesic (Holdings) Inc. from Sealbond Limited.

New major risk - Financial position

Virios Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Recent updates

Dogwood Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Price target increased by 92% to US$83.33

Virios Therapeutics, Inc. Appoints Angela Walsh as Chief Financial Officer

Virios Therapeutics, Inc. (NasdaqCM:VIRI) acquired Pharmagesic (Holdings) Inc. from Sealbond Limited.

New major risk - Financial position

Virios Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Virios Therapeutics, Inc. Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

New major risk - Revenue and earnings growth

Nasdaq Grants Exception Till October 28 to Virios Therapeutics to Regain Compliance with Minimum Bid Price Requirement

Virios Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

New major risk - Shareholder dilution

Virios Therapeutics, Inc. has filed a Follow-on Equity Offering.

Virios Therapeutics, Inc. Receives Another Letter from Nasdaq

Virios Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Virios Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

New major risk - Revenue and earnings growth

Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid

New major risk - Market cap size

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Insufficient new directors

New major risk - Financial position

Virios Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Virios Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New major risk - Market cap size

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Virios Therapeutics, Inc. Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as A New Treatment Option for Fibromyalgia

Virios Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-Covid Symptoms Following Treatment with A Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?

Virios Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023

Price target decreased to US$2.00

High number of new directors

Virios Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Virios Therapeutics Receives Letter Regarding Bid Price Requirement from the Listing Qualifications Department of the Nasdaq

Virios Therapeutics, Inc. Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

Virios Therapeutics slides 11% postmarket on proposed stock offering

Virios Therapeutics, Inc. Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

Virios Therapeutics GAAP EPS of -$0.44 beats by $0.07

Virios Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Virios Therapeutics, Inc.(NasdaqCM:VIRI) dropped from Russell Microcap Value Index

Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Founder & Director recently bought US$59k worth of stock

Virios Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new directors

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Virios Therapeutics Inc. Withdraws its Application for Investigational New Drug (IND 157311)

Virios Therapeutics, Inc. Achieves over 50% Enrollment Milestone in Its Phase 2B Clinical Trial for Fibromyalgia

Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Virios Therapeutics Receives New Patent for Antiviral Inhibitor Combination

Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Virios Therapeutics, Inc.(NasdaqCM:VIRI) dropped from Russell Microcap Growth Index

Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia

Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study

Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans

Virios Therapeutics, LLC to Report Q4, 2020 Results on Mar 18, 2021

Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel Syndrome

Virios Therapeutics gains 10% on research deal in irritable bowel syndrome